Ovarian carcinoma affects 10.2 per 100,000 women annually, and because it is rarely detected early, the five-year survival rate remains 50.9%. Advancing treatment depends on preclinical models that accurately replicate the disease.  

High-grade serous ovarian carcinoma is an aggressive malignancy influenced by both genetic and microenvironmental factors that shape tumor progression and therapy response. To model it, we developed a patient-derived system using high-grade serous ovarian carcinoma donors.

Here, we developed and applied a comprehensive patient derived model using high-grade serous ovarian carcinoma donors. OVC cultures incorporating dissociated tumor tissue, cancer-associated fibroblasts (CAFs) and endothelial cells were established using the OrganoPlate Graft Uniflow (UF) platform.

‍